The identification of these PD‐L1‐altered splicing events opens up new avenues for understanding the complex mechanisms driving castration‐resistant prostate cancer and presents opportunities for therapeutic intervention by targeting specific splicing patterns. Here, CD274 is linked to prostate carcinoma.